Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.
Mavacamten is a first-in-class oral small molecule myosin inhibitor developed for treating symptomatic obstructive hypertrophic cardiomyopathy. Synthesized via advanced organic chemistry, it features the molecular formula C24H28N6O3 and CAS No. 1907956-83-5.
Strictly contraindicated in patients with heart failure or reduced ejection fraction. Requires specialized storage at controlled room temperature away from moisture. Handling must adhere to GMP standards due to potent pharmacological activity.